solanezumab
Breakthrough Alzheimer’s Therapies Drive Early Detection Rates While Exposing Deep Treatment Disparities
Analysis from Komodo Health and Medscape Education shows cognitive screening up 10% and biomarker testing up 23%, yet significant disparities persist in detection for women and treatment access for Black...
Lilly launches global Alzheimer’s campaign with Julianne Moore
The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health
Rolling submission granted for Biogen/Eisai’s next Alzheimer’s antibody
The FDA will review the data for Biogen and Eisai’s anti-amyloid beta protofibril antibody, lecanemab, on an ongoing basis
Embattled Biogen talks up Aduhelm
Biogen CEO admitted the company was experiencing “near-term challenges” after the controversial approval of Alzheimer’s drug, Aduhelm
Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm
Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its dealings with the company.
Lilly restructures in preparation for Alzheimer’s drug launch
As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration
Lilly restructures in preparation for Alzheimer’s drug launch
As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration
Merck gets Alzheimer’s label claim for insomnia drug Belsomra
Alzheimer's patients typically experience poor sleep
Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials
Gained conditional approval in China in November
Are we ready for an Alzheimer’s disease modifying treatment
Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. But if a new therapy entered the market today, would healthcare systems be ready for...
Biogen and Eisai drop Alzheimer’s drug elenbecestat
Latest blow in string of failures for BACE inhibitor category